Q-omics provides the consensus-scored CASP7 profile across patient tissues and cancer cell-line models. CASP7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CASP7 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, CASP7 RNA expression shows 19,914 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, COAD, and UVM as cancer lineages where CASP7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CASP7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CASP7 survival associations across molecular data types. CASP7 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CASP7 RNA expression–survival associations across cancer types. High CASP7 expression shows unfavorable associations in ACC and LGG, but favorable associations in SKCM, STAD, BRCA and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CASP7 RNA expression.
This table summarizes CASP7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CASP7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CASP7 shows lower tumor expression in COAD, KICH, LUAD, LUSC and READ and higher tumor expression in HNSC. The COAD box plot shows higher CASP7 RNA expression in normal versus tumor tissue (log2 FC = −1.834, t-test p < 0.001).
This table shows molecular features associated with CASP7 in patient tissues and cancer cell lines. In patient samples, CASP7 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CASP7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and OESOPHAGUS.
